NAD+ appears in discussions about energy, aging, and an expanding range of wellness products. Before deciding what to make of those offers, it helps to understand the smaller, more precise statement underneath them: NAD is a coenzyme involved in essential cellular chemistry.
That biological role explains scientific interest. It does not, by itself, establish that buying more of a substance improves a person’s health. The interesting work begins when a study tests a particular intervention, in particular people, against a meaningful comparison.
THE USEFUL DISTINCTION
A molecule can be essential to normal biology without every product bearing its name having proven clinical benefits.
Is NAD+ a substrate or a product?
It depends on the reaction and the direction being described. In the alcohol-dehydrogenase example below, NAD+ is a substrate on the left. Read the equation in reverse and it becomes a product. Calling it a coenzyme describes a biochemical role; that does not prevent it from also being a reactant.
A useful way to read the figure is to cover one side and ask what must be supplied on the other side. Then reverse the question. This is a reading exercise, not an instruction to alter a pathway. Keep the reaction itself attached to the answer whenever you use the words substrate or product; a label detached from its example can sound more universal than the explanation warrants.
- Primary alcohol
- NAD+
- Aldehyde
- NADH
- H+
Schematic alcohol-dehydrogenase reaction. Left to right, NAD+ is a reactant; right to left, it is a product. The arrow does not predict what happens in a particular tissue.
Evidence: Reaction record
What the molecule name tells you
NAD abbreviates nicotinamide adenine dinucleotide. NAD+ denotes the oxidized form involved in electron transfer; NADH is its reduced partner. The NADH record describes two nucleotides connected through phosphate groups, with adenine in one and nicotinamide in the other. Use the plus notation to distinguish the named form, not as a rating of clinical strength or a claim about every physiological protonation state.
Where does NAD+ come from? The oral NR paper describes synthesis from tryptophan and recycling involving intermediates and vitamin B3 forms.
That background gives a reader vocabulary for asking a better question. It does not supply a personal diagnosis, a reason to choose a supplement, or an answer about a commercial preparation. If an advertisement jumps from a pathway name to a purchase recommendation, write down the missing step: what evidence connects the proposed intervention to the outcome that matters to this person? Our molecule comparison keeps the names separate while you examine that link.
Evidence: Molecule record / Related molecule / NR background
Cycling and consumption answer different questions
Redox cycling interconverts NAD+ and NADH without consuming the NAD molecule. Other reactions cleave it: the IV paper describes NAD-consuming enzymes including sirtuins and ADP-ribose-related enzymes. Its background discussion is not a finding that an infusion improved repair or aging.
When reading an explanation, identify which kind of use the author means. The loose phrase “uses NAD” leaves that question unanswered. A diagram of a process can help you follow the process, but it cannot tell you whether a particular person would benefit from a proposed purchase. Ask the writer to separate the explanation of normal chemistry from the evidence for intervening in it. That separation makes a discussion more precise without requiring the reader to dismiss the underlying research.
Three studies, three different questions
Use the table as a set of boundaries. Read across a row before comparing rows: what went into the study, who took part, how long it lasted, and what was measured? The final column identifies a question the design does not settle. This is a study map, with no effectiveness ranking and no numerical comparison of benefits across unlike experiments.
Martens reported NIH support and ChromaDex materials and partial funding.
The IV pilot disclosed commercial funding, donated preparation and investigator financial relationships.
Funding disclosures belong beside the methods and limitations. They are a reason to inspect how a result was obtained, not a substitute for reading it or an automatic verdict on its accuracy. None of the rows is a trial of the provider purchase you may be considering.
| Study | Ingredient and route | Participants and comparison | Duration | Measured endpoint | Boundary |
|---|---|---|---|---|---|
| Martens | Oral nicotinamide riboside (NR) | 30 randomized; 24 completed; healthy adults aged 55–79; placebo crossover | Six weeks per condition | Blood-cell NAD-related measures; exploratory physiology | Does not establish a provider product or longevity benefit |
| Grant | Intravenous NAD+ | 8 treated; 3 saline controls | Six-hour infusion; sampling over eight hours | Plasma and urine metabolites | Small, short pilot; does not establish lasting symptom relief |
| McDermott / NICE | Oral NR, with or without resveratrol | 90 participants with peripheral artery disease; placebo comparison | Six months | Walking performance | Condition-specific functional endpoint; not a wellness-injection trial |
Evidence: Martens et al.: oral NR randomized crossover trial / Grant et al.: 2019 IV NAD+ metabolome pilot / McDermott et al.: 2024 NICE trial
A biomarker is not the whole experience
A higher laboratory measurement is not automatically proof of better concentration, less fatigue, or a longer life. Researchers need appropriate clinical endpoints and study designs to test those claims. Short follow-up also limits what can be said about sustained benefit or long-term safety.
Some precursor research does examine clinical function in defined populations. That specificity matters: a condition-specific oral NR result should not become a blanket claim for injectable NAD+ in otherwise healthy adults.
Evidence: McDermott et al.: 2024 NICE trial / Dellinger et al.: 2017 NRPT randomized trial
Read a claim with a blank evidence card
Try this explicitly hypothetical example: an unnamed offer links to an unnamed study and says that its product is supported by research. No product, outcome or measurement is being invented here. The exercise is to decide what you would need to see before accepting that sentence.
- Copy the precise claim. Keep the promised outcome, the intended user and any time period together. Do not replace a vague claim with a stronger one of your own.
- Name the proposed intervention. Put the ingredient and route from the actual proposal in one box. Leave missing information blank.
- Name the studied intervention. Put the paper’s ingredient, route and comparison in another box, using the methods rather than the advertisement.
- Find the outcome. Record what the researchers actually measured. If the claimed outcome is absent, write “not answered here.”
- Record the remaining question. Ask the clinician to explain each mismatch and which evidence, if any, addresses it.
The result can be a useful question even when it is not a decision. For example, a reader may be able to identify the cited paper yet still need the selected product description. Keep that uncertainty visible. The evidence explorer provides another way to inspect study boundaries, and the route guide helps organize the next conversation.
Evidence: Reaction record
Bring the product back into view
Ask what exactly is being sold, what evidence matches it, and what the risks and costs are. A compounded injection raises preparation and sterility questions that an oral supplement trial cannot answer.
Read the safety explainer, route comparison, and offer reviews together. The purpose is to make a clinical conversation more informed, not to turn an appealing cellular story into a prescription decision.
Evidence: FDA: suitable ingredients for sterile compounding / FDA: compounding and approval
What this update checked
The November 7, 2026 update checked accessible chemical and enzyme records and the three original papers summarized above. It added the reaction diagram, study table and reading exercise. Older FDA references retained on this page were not newly verified: fresh FDA and NIH nutrition-source retrievals were unavailable. Their presence should not be read as a new regulatory or nutrition review. This remains public-source editorial research, without completed clinician review or a test of a commercial product.
Evidence: Molecule record / Reaction record
Open the source material
- Reaction record
Enzyme reference; checked November 7, 2026.
- Molecule record
Chemical identity; checked November 7, 2026.
- Related molecule
ChEBI description reproduced by PubChem; checked November 7, 2026.
- NR background
Biochemical context within the original paper; checked November 7, 2026.
- Grant et al.: 2019 IV NAD+ metabolome pilot
Eight NAD+ recipients and three saline controls; short-term metabolite measurements, not a longevity or clinical efficacy trial.
- Martens et al.: oral NR randomized crossover trial
Original oral NR research; not provider-product validation.
- McDermott et al.: 2024 NICE trial
Randomized trial in peripheral artery disease. A condition-specific oral NR result is not general proof for all NAD products.
- Dellinger et al.: 2017 NRPT randomized trial
120 adults aged 60–80, eight weeks; NAD+ biomarker and safety outcomes. Elysium funded the study; not evidence of longer life.
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
